Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Merck & Co., Inc. (MRK): Will Dividends Keep Going Strong?

Merck & Co., Inc. (NYSE:MRK)Throughout the years, some of the best performing pharmaceutical industry stocks have had long histories of providing healthy dividends to their stockholders. Merck & Co., Inc. (NYSE:MRK), for instance, a Big Pharma offering a number of healthcare solutions predominantly via its prescription meds, is well known for also providing a nice steady dividend income stream to its investors.

Where Merck is headed

In addition to its vaccines, biologic therapies, prescription drugs, and consumer care products, Merck & Co., Inc. (NYSE:MRK) is also well entrenched in the area of offering animal health products and services. Some of Merck’s top sellers in the human arena include its asthma drug Singulair, as well as Januvia for diabetes, and both Vytorin and Zetia for the management of high cholesterol.

Over the past 12 months, Merck & Co., Inc. (NYSE:MRK) has seen a continuation of expanding profit margins – coupled with a rise in its share price. The company currently pays its shareholders a $1.72 per share dividend, which equates to a dividend yield of almost 4% – a nice yield in comparison to other potential income producing vehicles.

Moving forward with new cures

Recently, Merck & Co., Inc. (NYSE:MRK)s insomnia drug Suvorexant was accepted for standard review by the FDA – meaning that if this med gains approval, it will essentially be the first of its kind in a brand new classification of medications- referred to as orexin receptor antagonists- that can be utilized with those who have a difficult time either falling, or staying, asleep.

The potential profit to Merck & Co., Inc. (NYSE:MRK) for this drug alone is nothing to yawn about. It has been estimated that the market sector for this particular med is in the range of $2.7 billion. In addition, Merck & Co., Inc. (NYSE:MRK)’s recent purchase of the ovarian cancer drug Vintafolide from Endocyte – while facing some potential competition from Eli Lilly & Co. (NYSE:LLY)’s similar offering – could still payout nicely over the next 5 to 10 years in the massive $2.3 billion market for cancer drugs.

Merck also “plays well with others” in seeking additional profit potential. An upcoming mid-stage clinical trial of a hepatitis C virus drug in conjunction with Bristol Myers Squibb Co. (NYSE:BMY) will use a combination of Merck’s MK-5172 and Bristol Myers Squibb Co. (NYSE:BMY)’ Daclatasvir drug.

The trial will test to evaluate the efficacy and the safety of a once-per-day oral ingestion of the medication. If all goes well, this could help to build on the success of Merck’s already approved hepatitis C drug Victrelis that hit the market in 2011.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.